Olema is a clinical-stage biopharmaceutical company developing targeted therapies for breast cancer and other endocrine-driven cancers. The company's lead program, palazestrant, is an orally available small molecule that acts as both a complete estrogen receptor antagonist and selective estrogen receptor degrader, designed to overcome limitations of existing endocrine therapies in estrogen receptor-positive breast cancer. Olema also develops OP-3136, a selective KAT6 inhibitor for breast and other solid tumors. The company owns worldwide development and commercialization rights to its product candidates and intends to generate revenue through commercial sales either independently or with partners, while relying on contract manufacturing organizations for production and collaborating with major pharmaceutical companies like Novartis and Pfizer on clinical development and supply arrangements.